Dataset from A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Empagliflozin (10 mg and 25 mg) Administered Orally Once Daily in Combination With Insulin With or Without up to Two Oral Anti-diabetic Agents for 24 Weeks in Chinese Type 2 Diabetic Patients With Insufficient Glycemic Control.

This is a study in Chinese adults with type 2 diabetes. The study is open to people who take
insulin but still have too high blood sugar levels. Participants may additionally be taking
up to 2 other medicines for their diabetes. The purpose of this study is to find out whether
empagliflozin taken together with insulin helps people with type 2 diabetes to better control
their blood sugar.

The participants are in the study for about 7 months. During this time, they visit the study
site about 8 times, 1 additional visit may be either a visit to the study site or a phone
call. At the start of the study, participants are put into 3 groups by chance. Participants
get either 10 mg empagliflozin tablets, or 25 mg empagliflozin tablets, or placebo tablets
once a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine.

The doctors regularly take blood samples from the participants. The changes in blood sugar
levels are compared between the groups. The doctors also check the general health of the
participants.